Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.
Adult
Aged
Aged, 80 and over
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
B-Lymphocytes
/ immunology
COVID-19
/ complications
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
/ immunology
Male
Middle Aged
Prognosis
SARS-CoV-2
/ immunology
T-Lymphocytes
/ immunology
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
17
06
2021
accepted:
13
09
2021
revised:
08
09
2021
pubmed:
27
9
2021
medline:
15
2
2022
entrez:
26
9
2021
Statut:
ppublish
Résumé
We studied clinical and immunological outcome of Covid-19 in consecutive CLL patients from a well-defined area during month 1-13 of the pandemic. Sixty patients (median age 71 y, range 43-97) were identified. Median CIRS was eight (4-20). Patients had indolent CLL (n = 38), had completed (n = 12) or ongoing therapy (n = 10). Forty-six patients (77%) were hospitalized due to severe Covid-19 and 11 were admitted to ICU. Severe Covid-19 was equally distributed across subgroups irrespective of age, gender, BMI, CLL status except CIRS (p < 0.05). Fourteen patients (23%) died; age ≥75 y was the only significant risk factor (p < 0.05, multivariate analysis with limited power). Comparing month 1-6 vs 7-13 of the pandemic, deaths were numerically reduced from 32% to 18%, ICU admission from 37% to 15% whereas hospitalizations remained frequent (86% vs 71%). Seroconversion occurred in 33/40 patients (82%) and anti-SARS-CoV-2 antibodies were detectable at six and 12 months in 17/22 and 8/11 patients, respectively. Most (13/17) had neutralizing antibodies and 19/28 had antibodies in saliva. SARS-CoV-2-specific T-cells (ELISpot) were detected in 14/17 patients. Covid-19 continued to result in high admission even among consecutive and young early- stage CLL patients. A robust and durable B and/or T cell immunity was observed in most convalescents.
Identifiants
pubmed: 34564699
doi: 10.1038/s41375-021-01424-w
pii: 10.1038/s41375-021-01424-w
pmc: PMC8475381
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
476-481Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Leukemia. 2020 Nov;34(11):3047-3049
pubmed: 32855439
Blood. 2020 Sep 3;136(10):1134-1143
pubmed: 32688395
Haematologica. 2017 Mar;102(3):562-572
pubmed: 27927767
J Am Geriatr Soc. 1995 Feb;43(2):130-7
pubmed: 7836636
J Infect Dis. 2021 Aug 2;224(3):407-414
pubmed: 33978762
Cell Rep Med. 2021 Jun 15;2(6):100290
pubmed: 33969322
Nat Rev Immunol. 2020 Dec;20(12):727-738
pubmed: 33139888
Sci Immunol. 2020 Dec 23;5(54):
pubmed: 33361161
Leukemia. 2021 Sep;35(9):2703-2705
pubmed: 33986431
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
J Clin Immunol. 2021 Aug;41(6):1146-1153
pubmed: 33983545
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
Nat Med. 2021 May;27(5):892-903
pubmed: 33767405
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Hemasphere. 2021 Apr 26;5(5):e564
pubmed: 33912812
Leuk Lymphoma. 2015 Jan;56(1):42-8
pubmed: 24717109
Acta Haematol. 2021;144(5):508-518
pubmed: 33631756
Leukemia. 2019 Oct;33(10):2527-2530
pubmed: 31086260
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33483360
Leukemia. 2020 Sep;34(9):2354-2363
pubmed: 32647324